Press release
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billion by 2030
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+ breast cancer accounts for roughly 15-20% of all breast cancer cases globally and is associated with aggressive tumor biology, high recurrence rates, and significant unmet clinical need in metastatic settings.
The market continues to accelerate as novel HER2-targeted mechanisms-including HER2xHER3 inhibitors, HER2-directed ADCs, bispecific antibodies, and personalized genomic-guided treatment pathways-show exceptional clinical efficacy.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73655
Key Takeaways
• Market Size (2023): USD 13.82 Billion
• Expected Market Size (2030): USD 21.46 Billion
• CAGR (2024-2030): 6.5%
• Dominated by targeted biologics, ADCs, and dual inhibition strategies.
• Top companies include Roche/Genentech, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Seagen, Merck, Amgen, Eli Lilly, and GSK.
• Precision oncology tools-liquid biopsies, NGS panels, AI-driven HER2 scoring-are gaining rapid adoption globally.
Market Story
Treatment of HER2+ breast cancer has shifted dramatically with the emergence of multi-mechanism targeted therapy regimens.
1. Antibody-Drug Conjugates (ADCs) Drive Revenue Leadership
ADCs are expanding across early-stage and metastatic HER2+ settings:
• Trastuzumab deruxtecan (Enhertu) - global blockbuster
• Ado-trastuzumab emtansine (T-DM1) - adjuvant & metastatic use
• Next-generation HER2 ADCs with improved payload delivery
ADCs now represent the fastest-growing treatment class in HER2+ oncology.
2. Dual-Targeted & Combination Therapies Expand
Combining HER2 inhibitors enhances progression-free survival:
• Trastuzumab + Pertuzumab (CLEOPATRA standard)
• HER2 + HER3 targeted inhibitors
• HER2 blockers + CDK4/6 inhibitors
• Immunotherapy + HER2-directed combinations
These regimens are widely adopted for first-line metastatic therapy.
3. Novel HER2-Directed Small Molecules Gain Traction
Oral targeted therapies include:
• Tucatinib
• Neratinib
• Lapatinib
• Brain-penetrant TKIs for HER2+ brain metastases
These address unmet need for CNS involvement, common in metastatic HER2+ disease.
4. Precision Oncology & Genomic Testing Transform Diagnostics
Growth in diagnostics includes:
• NGS-based HER2 mutation profiling
• Liquid biopsy (ctDNA) monitoring
• AI-driven tumor imaging for HER2 scoring
• Multi-omics stratification (RNA, proteomics)
This increases accuracy in treatment selection and early relapse detection.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/73655/human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-clinical-market
Market Segments
By Therapy Class
• Antibody-Drug Conjugates (ADCs)
• Monoclonal Antibodies (Trastuzumab, Pertuzumab)
• Tyrosine Kinase Inhibitors (TKIs)
• Immunotherapies (PD-1/PD-L1 combinations)
• Chemotherapy + Targeted Therapy Regimens
• Biosimilars
By Disease Stage
• Early-Stage HER2+ Breast Cancer
• Locally Advanced Disease
• Metastatic HER2+ Breast Cancer
• HER2-Mutant Breast Cancer (Non-Amplified)
By Route of Administration
• Intravenous
• Subcutaneous
• Oral (TKIs)
By End User
• Hospitals & Oncology Centers
• Specialty Clinics
• Research Institutes
• Home Infusion Settings (emerging)
By Region
• North America - highest biologic adoption
• Europe - strong biosimilar presence
• Asia-Pacific - fastest-growing due to rising HER2+ incidence
• Latin America
• Middle East & Africa
Recent Developments
• AstraZeneca & Daiichi Sankyo reported expanded approvals for Enhertu in early and metastatic settings.
• Roche launched new subcutaneous trastuzumab/pertuzumab combinations, improving patient convenience.
• Seagen advanced HER2 ADCs with novel linker-payload technologies.
• Pfizer & Novartis continued trials for next-generation TKIs targeting HER2-mutant disease.
• Merck initiated immunotherapy combination trials for HER2+ metastatic breast cancer.
• Genentech expanded AI-based tumor profiling partnerships.
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73655
Expert Quote
"HER2-positive breast cancer treatment is entering a precision-driven era powered by ADCs, genomic-guided therapy, and advanced biologics. These innovations are improving survival outcomes and reshaping the global oncology market."
-Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Market Drivers
• Increasing global breast cancer prevalence
• Expansion of high-efficacy ADCs
• Early diagnosis supported by AI and genomic screening
• Strong investment in HER2-targeted clinical trials
• Growing uptake of biosimilars improving treatment affordability
• Improved global funding for oncology care
• Rising incidence of HER2-mutant tumors beyond breast cancer
Forecast Outlook
The HER2+ Breast Cancer Clinical Market will reach USD 21.46 Billion by 2030, driven by:
• New ADC approvals
• Combination therapies with immuno-oncology agents
• Growth in NGS-based precision oncology
• Rising healthcare spending in Asia-Pacific
Regional Highlights
• U.S. maintains leadership due to advanced oncology infrastructure and rapid adoption of ADCs.
• Europe benefits from strong biosimilar integration and wide treatment access.
• Asia-Pacific sees fastest growth, driven by increasing incidence and expanding clinical trial sites.
Government & Regulatory Initiatives
• FDA accelerated approvals for HER2 ADCs
• EMA support for precision oncology and subcutaneous biologic combinations
• Japan PMDA early access pathways for innovative breast cancer drugs
• National screening programs improving early detection
• Reimbursement expansion for biologics and ADCs across global markets
Conclusion
The HER2-Positive Breast Cancer Market is advancing rapidly due to next-generation targeted therapies, ADC breakthroughs, precision diagnostics, and global adoption of biologics. Companies investing in HER2-focused multi-mechanism oncology platforms will dominate clinical and commercial opportunities through 2030.
This report is also available in the following languages : Japanese (ヒト上皮成長因子受容体2陽性乳がん(HER2陽性乳がん)臨床市場), Korean (인간 상피 성장 인자 수용체 2 양성 유방암(HER2+ 유방암) 임상 시장), Chinese (人表皮生长因子受体 2 阳性乳腺癌 (HER2+ 乳腺癌) 临床市场), French (Marché clinique du cancer du sein HER2+ (récepteur 2 du facteur de croissance épidermique humain positif)), German (Klinischer Markt für HER2-positiven Brustkrebs (HER2+ Brustkrebs)), and Italian (Mercato clinico del cancro al seno positivo al recettore del fattore di crescita epidermico umano 2 (cancro al seno HER2+)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73655
Our More Reports:
AI in Mental Health Market
https://exactitudeconsultancy.com/reports/73679/ai-in-mental-health-market
Behavioral Healthcare Software Market
https://exactitudeconsultancy.com/reports/73681/behavioral-healthcare-software-market
Wireless Electronic Health Records Market
https://exactitudeconsultancy.com/reports/73683/wireless-electronic-health-records-market
Patient Centric Healthcare App Market
https://exactitudeconsultancy.com/reports/73685/patient-centric-healthcare-app-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billion by 2030 here
News-ID: 4295315 • Views: …
More Releases from Exactitude Consultancy
Intracranial Hemorrhage (ICH) Clinical Market to Hit USD 2.94 Billion by 2030
Sub-Headline: The global Intracranial Hemorrhage Clinical Market is projected to grow from USD 1.92 billion in 2023 to USD 2.94 billion by 2030, reflecting a CAGR of 6.2%, driven by technological advancements in neurosurgical devices, AI-driven imaging, and novel hemostatic drug development.
Introduction
The Intracranial Hemorrhage (ICH) Clinical Market is experiencing sustained growth as emergency care centers, neurology hospitals, and trauma units adopt advanced neurodiagnostics and treatment technologies. ICH-including subarachnoid hemorrhage (SAH),…
Acquired Autoimmune Hemolytic Anemia (AIHA) Clinical Market to Reach USD 1.34 Bi …
Sub-Headline: The global Acquired Autoimmune Hemolytic Anemia (AIHA) Clinical Market is expected to grow from USD 820 million in 2023 to USD 1.34 billion by 2030, registering a CAGR of 7.1%, driven by rising incidence, improved diagnostics, and next-generation immunotherapies.
Introduction
The Acquired Autoimmune Hemolytic Anemia (AIHA) Clinical Market is growing steadily as advancements in targeted immunology, biologics, complement inhibitors, and B-cell-directed therapies reshape treatment strategies. AIHA is a rare but serious…
Amyotrophic Lateral Sclerosis (ALS) Clinical Market to Reach USD 1.72 Billion by …
Sub-Headline: The global ALS Clinical Market is projected to grow from USD 1.08 billion in 2023 to USD 1.72 billion by 2030, at a CAGR of 6.9%, driven by rising ALS prevalence, breakthrough therapeutics, and expanding clinical research pipelines across North America, Europe, and Asia-Pacific.
Introduction
The Amyotrophic Lateral Sclerosis (ALS) Clinical Market is undergoing a significant transformation as next-generation neurotherapeutics-including gene therapies, antisense oligonucleotides (ASOs), neuroprotective agents, and stem-cell-based treatments-move through…
Electric Aircraft Market is expected to reach USD 34.5 billion by 2034
Market Overview
The Electric Aircraft Market includes fixed-wing aircraft, rotorcraft, VTOL/eVTOL vehicles, drones, and hybrid-electric systems that use electric propulsion for improved efficiency, lower emissions, and reduced operating costs. The market is being shaped by advances in battery technology, lightweight materials, electric motors, power electronics, hydrogen-electric systems, and autonomous flight technologies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73864
In 2024, the market stands at USD 9.3 billion, driven by:
• Rising global…
More Releases for HER2
Evolving Market Trends In The HER2-Negative Breast Cancer Industry: Regulatory A …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Expected HER2-Negative Breast Cancer Market Size During the Forecast Period?
The market size of HER2-negative breast cancer has witnessed robust growth lately. With a projected growth at a compound annual growth rate (CAGR) of 8.1%, the market size will balloon from $16.29 billion in 2024 to reach $17.62 billion…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
